Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.

Today, molecular-profile-directed therapy is a guiding principle of modern thoracic oncology. The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons' professional competence. The European Society of Thoracic Surgeons (ESTS) Biology Club aims at providing a comprehensive insight into the basic biology of the diseases we are treating. During the 2013 ESTS Annual Meeting, different experts of the field presented the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.

[1]  C. la Vecchia,et al.  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Wistuba,et al.  The evolving genomic classification of lung cancer , 2013, The Journal of pathology.

[3]  Mary Beth Landrum,et al.  Tumor boards and the quality of cancer care. , 2013, Journal of the National Cancer Institute.

[4]  A. Marchetti,et al.  Strategies for improving outcomes in NSCLC: a look to the future. , 2013, Lung cancer.

[5]  M. Fassan,et al.  Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel , 2013, PloS one.

[6]  M. Esteller,et al.  A prognostic DNA methylation signature for stage I non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Pedro Madureira,et al.  EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. , 2013, Pharmacogenomics.

[8]  N. Girard,et al.  Comparisons of microRNA Patterns in Plasma before and after Tumor Removal Reveal New Biomarkers of Lung Squamous Cell Carcinoma , 2013, PloS one.

[9]  A. Martínez-Torteya,et al.  SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis , 2013, PloS one.

[10]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[11]  M. Tsao,et al.  Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study. , 2013 .

[12]  D. Beer,et al.  Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer. , 2013, Thoracic surgery clinics.

[13]  A. Nicholson,et al.  Antibody independent microfluidic cell capture of circulating tumor cells for the diagnosis of cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  H. Pass,et al.  Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. , 2012, The New England journal of medicine.

[15]  Stephen A. Williams,et al.  Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool , 2012, PloS one.

[16]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[17]  H. Pass,et al.  Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. , 2012, Cancer research.

[18]  M. Turina,et al.  European Journal of Cardio-Thoracic Surgery celebrates its 25th anniversary: 1987-2012. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[19]  H. Rehrauer,et al.  Role of Hedgehog Signaling in Malignant Pleural Mesothelioma , 2012, Clinical Cancer Research.

[20]  D. Berry,et al.  Benefits and harms of CT screening for lung cancer: a systematic review. , 2012, JAMA.

[21]  K. Nackaerts,et al.  Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Skates,et al.  Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best? , 2011, Lung cancer.

[23]  A. Chella,et al.  Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Nikolina Radulovich,et al.  Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer , 2011, Proceedings of the National Academy of Sciences.

[25]  Elaine R. Mardis,et al.  A decade’s perspective on DNA sequencing technology , 2011, Nature.

[26]  Ugo Pastorino,et al.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer , 2011, Proceedings of the National Academy of Sciences.

[27]  C. Reed,et al.  Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers. , 2010, The Journal of thoracic and cardiovascular surgery.

[28]  A. Chella,et al.  Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma , 2010, The International journal of biological markers.

[29]  H. Pass,et al.  Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation , 2010, Proceedings of the National Academy of Sciences.

[30]  M. Ladanyi,et al.  Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels , 2010, Clinical chemistry and laboratory medicine.

[31]  A. Cesario,et al.  Osteopontin is not a specific marker in malignant pleural mesothelioma. , 2009, The International journal of biological markers.

[32]  G. Gordon,et al.  Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. , 2009, Journal of the National Cancer Institute.

[33]  L. Stitt,et al.  New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. , 2009, Clinical chemistry.

[34]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[35]  Phillip A Sharp,et al.  Suppression of non-small cell lung tumor development by the let-7 microRNA family , 2008, Proceedings of the National Academy of Sciences.

[36]  M. Copin,et al.  Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment , 2007, Clinical Cancer Research.

[37]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[38]  G. Gordon,et al.  Transcriptional profiling of mesothelioma using microarrays. , 2005, Lung cancer.

[39]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[40]  R. Myers,et al.  Quality assessment of the human genome sequence , 2004, Nature.

[41]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[42]  A. Musk,et al.  Mesothelin-family proteins and diagnosis of mesothelioma , 2003, The Lancet.

[43]  D. Sugarbaker,et al.  Multimodality therapy for malignant pleural mesothelioma. , 1997, Chest.

[44]  Ugo Pastorino,et al.  Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. , 2009, American journal of respiratory and critical care medicine.

[45]  Zhandong Liu,et al.  Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. , 2005, The New England journal of medicine.